Evidence map›Paper›PMID 33467058›Full record

ArticleInternational journal of molecular sciences2021

P2Y11 Agonism Prevents Hypoxia/Reoxygenation- and Angiotensin II-Induced Vascular Dysfunction and Intimal Hyperplasia Development.

Marie Piollet, Adrian Sturza, Stéphanie Chadet, Claudie Gabillard-Lefort, Lauriane Benoist, Danina-Mirela Muntean, Oana-Maria Aburel, Denis Angoulvant, Fabrice Ivanes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Marie PiolletEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.
Adrian SturzaDepartment of Functional Sciences-Pathophysiology, Center for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy Timișoara, 300041 Timișoara, Romania.
Stéphanie ChadetEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.
Claudie Gabillard-LefortEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.
Lauriane BenoistEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.
Danina-Mirela MunteanDepartment of Functional Sciences-Pathophysiology, Center for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy Timișoara, 300041 Timișoara, Romania.
Oana-Maria AburelDepartment of Functional Sciences-Pathophysiology, Center for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy Timișoara, 300041 Timișoara, Romania.
Denis AngoulvantEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.ORCID 0000-0003-0788-8092
Fabrice IvanesEA4245 Transplantation, Immunology and Inflammation Laboratory, Loire Valley Cardiovascular Collaboration, University of Tours, 37000 Tours, France.
Université de Tours · FRVictor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

Fédération Française de Cardiologie no grant numberRomania-France Cooperation Mobilities Program "Brancusi-Hubert Curien" no grant number
6 · The paper itself

Abstract

Vascular dysfunction in cardiovascular diseases includes vasomotor response impairments, endothelial cells (ECs) activation, and smooth muscle cells (SMCs) proliferation and migration to the intima. This results in intimal hyperplasia and vessel failure. We previously reported that activation of the P2Y11 receptor (P2Y11R) in human dendritic cells, cardiofibroblasts and cardiomyocytes was protective against hypoxia/reoxygenation (HR) lesions. In this study, we investigated the role of P2Y11R signaling in vascular dysfunction. P2Y11R activity was modulated using its pharmacological agonist NF546 and antagonist NF340. Rat aortic rings were exposed to angiotensin II (AngII) and evaluated for their vasomotor response. The P2Y11R agonist NF546 reduced AngII-induced vascular dysfunction by promoting EC-dependent vasorelaxation, through an increased nitric oxide (NO) bioavailability and reduced AngII-induced H

Indexed as

Angiotensin IIAnimalsAortaDiphosphonatesEndothelin-1HumansHuman Umbilical Vein Endothelial CellsHyperplasiaMaleMyocytes, Smooth MuscleNaphthalenesulfonatesNitric OxideNitric Oxide Synthase Type IIIPurinergic P2 Receptor AgonistsRatsRats, Wistar4,4'-(carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-(4-methylphenylene)carbonylimino))bis(1,3-xylene-alpha,alpha'-diphosphonic acid)Angiotensin IIDiphosphonatesEndothelin-1NaphthalenesulfonatesNitric OxideNitric Oxide Synthase Type IIIP2RY11 protein, humanPurinergic P2 Receptor AgonistsReceptors, Purinergic P2Watercardiovascular protectionischemia reperfusion injuryP2Y purinoreceptorvascular dysfunction

Identifiers

PMID33467058
PMCPMC7829863
OpenAlexW3125698488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.